Iterion Therapeutics
PrivateLast Round
Grant
Feb 16, 2022
Total Funding Raised
$41.91M
Company Overview
Iterion Therapeutics is a clinical-stage biopharmaceutical company that develops novel targeted cancer therapeutics, including its lead product tegavivint, a first-in-class small molecule inhibitor of TBL1.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iterion Therapeutics Comparables
Compare Iterion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sapience Therapeutics | 85% | |
| Redx Pharma Plc | 82% | |
| StemSynergy Therapeutics, Inc. | 81% | |
Iterion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 16, 2022 | ||||
| Series B | Feb 16, 2021 | ||||
| Series B | Dec 5, 2018 | ||||
| Grant | Feb 19, 2014 |
Iterion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GOOSE Capital | Series B |
| GPG Ventures | Series B |
| Viva BioInnovator | Series B |
| Venture Investors LLC | Series B |
| Lumira Ventures | Series B |
| Cancer Prevention and Research Institute of Texas | Grant |
| AngelMD | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 16, 2022
Received $3M from the Cancer Prevention and Research Institute of Texas.
- Feb 19, 2014
$16M grant from Cancer Prevention and Research Institute of Texas.
Iterion Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Iterion Therapeutics's valuation, stock price, and market status.